Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Monthly Emicizumab Shows Value in Bleed Control

Publish date:: May 1, 2019

Key clinical point: For many patients with hemophilia A, with or without inhibitors, monthly treatment with emicizumab is enough to ensure a high level of bleed control.

Major finding: Twenty-three out of 41 patients (56.1%) reported no treated bleeds.

Study details: An ongoing, open-label phase 3 trial involving patients aged 12 years and older with severe congenital hemophilia A or hemophilia A with FVIII inhibitors who were receiving treatment with bypassing agents or FVIII concentrates.

Disclosures: F. Hoffman-La Roche and Chugai funded the study. The investigators reported financial relationships with the study sponsors and other companies.

Citation:

Pipe SW et al. Lancet Haem. 2019 Apr 16. doi: 10.1016/S2352-3026(19)30054-7.

This Week's Must Reads

Repeat LTBI Testing Best in Patients Taking Biologics With New Risk Factors,

Moderate coffee intake associated with few seizures in drug-refractory patients with epilepsy,

Scalp EEG predicts temporal lobe resection success,

A triple-antibiotic cure for Crohn’s disease?,

NFIX could be a target for sickle cell therapy,

Must Reads in Hematology

NFIX could be a target for sickle cell therapy,

Study halted; ‘hyperprogression’ seen with nivolumab for R/R PTCL,

Updated International Consensus Recommendations on Management of Acute Upper GI Bleeding,

Global Blood Supply Runs Low,

New Consensus Recommendations on Bleeding in Acquired Hemophilia,